NCT03478020 (DDI-COC) is a Phase 1 clinical trial of AQX-1125 in Healthy Volunteer, sponsored by Aquinox Pharmaceuticals (Canada) Inc..

Who is sponsoring NCT03478020?

NCT03478020 is sponsored by Aquinox Pharmaceuticals (Canada) Inc..

What drugs are being tested in NCT03478020?

Interventions in NCT03478020: AQX-1125, Combined Oral Contraceptive.

What condition does NCT03478020 study?

NCT03478020 studies Healthy Volunteer.

Is NCT03478020 still recruiting?

NCT03478020 is currently completed. Last updated 13 June 2018.

Last reviewed 2018-06-13 · How we verify

NCT03478020: DDI-COC

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Oral AQX-1125 and Combination Oral Contraceptive Drug-Drug Interaction Study

Completed Phase 1 Last updated 13 June 2018

What this trial tests

Phase 1 trial testing AQX-1125 in Healthy Volunteer in 32 participants. Completed in 5 April 2018.

Timeline

22 November 2017

Primary endpoint
29 March 2018

5 April 2018

Quick facts

Lead sponsor	Aquinox Pharmaceuticals (Canada) Inc.
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	32
Start date	22 November 2017
Primary completion	29 March 2018
Estimated completion	5 April 2018
Sites	1 location across Netherlands

Drugs / interventions tested

AQX-1125 — full drug profile →
Combined Oral Contraceptive — full drug profile →

Conditions studied

Healthy Volunteer — all drugs for Healthy Volunteer →

Sponsor

Aquinox Pharmaceuticals (Canada) Inc. — full company profile →

Who can join

Adults 18 to 45, female only, with Healthy Volunteer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open-label, fixed sequence, 4 cycle, drug-drug interaction (DDI) study of AQX-1125 in healthy female subjects on combination oral contraceptives (COC).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Healthy Volunteer

Currently open trials in the same condition.

NCT06274749 — Effects of Urolithin A Supplementation on Glucose Metabolism in Healthy Adults 55 >= Years Old: A Randomized Triple-Mask · NA · recruiting
NCT05652478 — Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized Study · Phase 2 · recruiting
NCT06845176 — Combining Motor Imagery and Tendon Vibration on the Effectiveness of Motor Imagery · NA · recruiting
NCT07439263 — Single Ascending Dose Study of HB2198 in Healthy Participants · Phase 1 · recruiting
NCT07220122 — Impact of Exogenous Ketones on Breathing in Healthy Volunteers · EARLY_PHASE1 · recruiting

Other Aquinox Pharmaceuticals (Canada) Inc. trials

Trials by the same sponsor.

NCT03500159 — Efficacy and Safety of AQX-1125 in Subjects With Chronic Prostatitis/Chronic Pelvic Pain Syndrome · Phase 2 · terminated
NCT03185195 — Phase 1 Absorption Distribution Metabolism and Excretion of AQX-1125 · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03478020 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Aquinox Pharmaceuticals (Canada) Inc.
Last refreshed: 13 June 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03478020.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing